Latest News
- Min. Nadda Unveils ?13,000-Crore Bio-Pharma SHAKTI and Chemical Parks Push to Expand India’s Global Chemicals and Biologics Footprint
- Aurobindo Pharma Subsidiary Launches Generic Cancer Drug in US, Expands Oncology Portfolio in Global Generics Market
- KIMS Hospitals Introduces Adaptive Deep Brain Stimulation in India for Advanced Parkinson’s Treatment
Russia starts production of IVF drugs
The clinical trials for these drugs will be held in Yekaterinburg.
According to TASS, Aleksandr Petrov, Chairman of the Board of Directors of OOO "Zavod Medsintez," there is a possible risk that drugs for the treatment of female infertility will disappear from the Russian market. Most drugs for women's reproductive health in Russia are currently imported, and if such supplies are cut off, IVF programmes will become impossible.
Petrov stated that Ural-based Zavod Medsintez has already begun production of recombinant follicle stimulating hormone and is planning to produce two additional drugs in the near future.
"There is a raw material shortage in the production of human chorionic gonadotropin, and we will produce this hormone using biotechnology, which is also an import substitution project," Aleksandr Petrov explained.
Medsintez announced its intention to expand its IVF drug portfolio in August 2022. "Normally, the launch of a drug takes three to five years, depending on clinical trials," Petrov said at the time, adding that clinical trials for these drugs will be held in Yekaterinburg.